Evista 60 DAIICHI SANKYO
€57.00
Description
About Evista 60 DAIICHI SANKYO, purpose and chemical nature
Evista 60 DAIICHI SANKYO, known generically as Raloxifene, is a medication primarily used for the prevention and treatment of osteoporosis in postmenopausal women. It belongs to a class of drugs called selective estrogen receptor modulators (SERMs), primarily functioning by mimicking estrogen’s beneficial effects on bone density without inducing some of the adverse effects associated with estrogen therapy. The chemical structure of Raloxifene allows it to selectively bind to estrogen receptors, exerting estrogen-like effects in certain tissues, such as bone, while blocking estrogen’s effects in others, like breast and uterine tissues. This unique role makes Evista a notable option for improving bone health in populations at risk for osteoporosis.
Mechanism of action, internal processes in the body
Evista 60 operates through a sophisticated mechanism that revolves around its selective action on estrogen receptors found primarily within bone and connective tissues. When Raloxifene binds to these estrogen receptors, it stimulates bone formation and decreases bone resorption, thus reducing the risk of fractures and enhancing overall bone integrity. Furthermore, Raloxifene exerts positive discontinuous effects on cholesterol levels, which may contribute to cardiovascular health, although this is not its primary indication. The overall consequence of these internal processes sustains and improves bone mass, while simultaneously eliminating the estrogen-related risks of breast and endometrial cancers, providing a multi-faceted approach to women’s health.
Side effects, how to prevent them
While Evista 60 DAIICHI SANKYO is generally well-tolerated, it is essential to be aware of potential side effects. Common adverse effects may include hot flashes, leg cramps, and an increased risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism. It’s crucial for users, particularly those with a history of blood clots, to consult healthcare professionals before starting therapy. Preventative strategies include staying hydrated, engaging in regular physical activity, and maintaining a balanced diet rich in calcium and vitamin D to support overall bone health. Additionally, routine health check-ups can help in monitoring any abnormalities and addressing them promptly, minimizing the potential risks associated with the drug.
How to Buy Evista 60 DAIICHI SANKYO in Great Britain, verified seller and guarantees
Purchasing Evista 60 DAIICHI SANKYO in Great Britain requires the user to follow legitimate channels to ensure quality and authenticity. It is advisable to buy the medication through accredited pharmacies and healthcare providers who possess proper licensing. Online pharmacies should be verified by organizations such as the General Pharmaceutical Council (GPhC) to ensure compliance with UK regulations. Seeking a prescription from a qualified healthcare professional before purchase can also guarantee that the product is appropriate for the individual’s health needs, thereby minimizing risks associated with misuse. Many reputable sellers offer guarantees on the quality of their products, allowing consumers peace of mind when making health-related purchases.
Results and conclusions, summary of user experience.
The overall experience of users with Evista 60 DAIICHI SANKYO has been positive, particularly among those utilizing it for osteoporosis management. Many report improvements in bone density, as evidenced by clinical studies that demonstrate a reduction in fracture rates. Users have noted the convenience of a once-daily dosage, which supports adherence to treatment. In terms of side effect profiles, while some individuals experience mild discomfort, the majority find them manageable and less impactful than the benefits obtained. The balancing act of reducing osteoporosis risk while minimizing cancer risk presents Evista as a valuable treatment option. As with any medication, user experiences may vary, emphasizing the importance of professional consultation for tailored advice. Overall, Evista 60 serves as a vital tool in enhancing women’s health, particularly for postmenopausal individuals targeting improved bone strength and cardiovascular health.
Additional information
| Active substance | Raloxifene |
|---|---|
| Active Half-Life | 24 hours |
| Classification | SERM |
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | Not specific, general liver function tests may be monitored |
| Also known as | Raloxifene hydrochloride |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Typically has no significant effect on blood pressure |
| Trade name | Evista |
| Storage conditions | Store at room temperature, protect from moisture and heat |
| Chemical name | [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride |
| Formula | C28H27NO4SВ·HCl |
| Substance class | Selective Estrogen Receptor Modulator (SERM) |
| Main action | Estrogen receptor modulator |
| Half-life | Approximately 27.7 hours |
| Dosage (medical) | Commonly prescribed as 60 mg per day |
| Dosage (sports) | Not typically used in sports for performance enhancement |
| Effects | Reduces the risk of osteoporosis, decreases total and LDL cholesterol |
| Side effects | Hot flashes, leg cramps, increased risk of venous thromboembolism, stroke |
| Use in sports | None, as it is not known for performance enhancement |
| Manufacturer | Daiichi Sankyo |




Reviews
There are no reviews yet.